COVID-19 Clinical Trial
— DICOPERIAOfficial title:
Differential Diagnosis of Persistent COVID-19 by Artificial Intelligence
The pandemic caused by SARS-CoV-2 infection has resulted, in addition to the well-known acute symptoms, in the emergence of persistent, diffuse and heterogeneous symptoms referred to as persistent COVID. Common symptoms include fatigue, shortness of breath, and cognitive dysfunction, among others, and result in an impact on daily functioning. Symptoms may be new onset, appear after initial recovery from an acute episode of COVID-19, or persist after the initial illness. Cardiac variability (HRV) was initially used in COVID-19 to predict mortality in the acute setting. Dysautonomia which partly evaluates HRV is frequent in patients with persistent COVID. Several groups have used voice or other respiratory noise analysis for the diagnosis of acute COVID. Patients in the persistent COVID cohort will be able to be differentiated from an age, sex and vaccination status matched cohort of recovered COVID patients without sequelae by means of a model created by Machine Learning that will be trained using cardiac variability (HRV), skin conductance and acoustic analysis data. The primary objetive will be to obtain a classification algorithm by Machine Learning to differentiate the group of patients with persistent COVID diagnosis from the paired group of recovered COVID patients without sequelae.
Status | Not yet recruiting |
Enrollment | 136 |
Est. completion date | November 2023 |
Est. primary completion date | November 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Persistent COVID group: Inclusion Criteria: - Age =18 and =70 years of age - Confirmed infection (PCR) with SARS- CoV-2 until 03/28/2022 and thereafter date. - Symptoms include: fatigue, respiratory distress or cognitive dysfunction, among others. - Symptoms persist or appear more than 3 months after onset of infection. - Symptoms last longer than 2 months and are not better explained by another diagnosis. - Symptoms appeared after initial recovery or persisted since disease debut. - Symptoms may fluctuate or remit over time. - Patients have capacity to consent and agree to participate in the study. Exclusion Criteria: - Active COVID-19 infection. - Cardiac arrhythmia, pacemaker carrier. - Other pathologies with dysautonomia. - Raynaud's phenomenon. - Other diseases that may affect exercise capacity or be aggravated by exercise shall also be excluded, such as: Uncontrolled heart failure, severe or symptomatic aortic stenosis, pulmonary edema, acute respiratory failure, recent pulmonary thromboembolism, lower limb thrombosis, infections, thyrotoxicosis, or orthopedic inability to walk. Recovery COVID group Inclusion Criteria: - Age =18 and =70 years of age - Confirmed infection (PCR) with SARS- CoV-2 until 03/28/2022 and thereafter date. - Full functional recovery. - Follow-up by Primary Care. - They have not presented three months after the onset of the disease: fatigue, respiratory distress or cognitive dysfunction, among others. - Patients have capacity to consent and agree to participate in the study. Exclusion Criteria: - Active COVID-19 infection. - Cardiac arrhythmia, pacemaker carrier. - Other pathologies with dysautonomia. - Raynaud's phenomenon. - Other diseases that may affect exercise capacity or be aggravated by exercise such as: uncontrolled heart failure, severe or symptomatic aortic stenosis, pulmonary edema, acute respiratory failure, recent pulmonary thromboembolism, lower limb thrombosis, infections, thyrotoxicosis, or orthopedic inability to walk shall also be excluded. |
Country | Name | City | State |
---|---|---|---|
Spain | Complexo Hospitalario Universitario de Ourense | Ourense | |
Spain | Health Center A Cuña | Ourense | |
Spain | Health Center Novoa Santos | Ourense | |
Spain | Health Center Valle Inclán | Ourense | |
Spain | S.S. Computer Engineering (University of Vigo) | Ourense | |
Spain | Galicia Sur Health Research Institute (IISGS) - Hospital Álvaro Cunqueiro | Vigo | |
Spain | School of Telecommunication Engineering (University of Vigo) | Vigo |
Lead Sponsor | Collaborator |
---|---|
Fundacin Biomedica Galicia Sur | Galician South Health Research Institute, University of Vigo |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Age | Years | 8 weeks | |
Other | Sex | Male, Female | 8 weeks | |
Other | Current treatment | Treatment taken by the patient at the time of the study. | 8 weeks | |
Other | Date of PCR + SARS-CoV-2 | DD-MMM-YYYY | 8 weeks | |
Other | Epidemic wave | Of the 7 waves of COVID-19 that have occurred in Spain, a description will be given of the wave to which the infection of each patient included belonged. First, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth wave. | 8 weeks | |
Other | Vaccination status at the time of infection | Number of vaccines doses at the time of infection | 8 weeks | |
Other | FVC | Is the maximum volume of air exhaled, with the maximum possible effort, starting from a maximum inspiration in ml. | 8 weeks | |
Other | FEV1 | The volume of air expelled during the first second of forced expiration in ml. | 8 weeks | |
Other | FEV1/ FVC | Expressed as a percentage (%), it indicates the proportion of the FVC that is expelled during the first second of the forced expiratory maneuver. | 8 weeks | |
Other | CO diffusion test | To evaluate the transfer of oxygen from the alveolar space to the hemoglobin of the erythrocytes contained in the pulmonary capillaries. Effective alveolar-capillary area available for gas transfer in the lung. (%) | 8 weeks | |
Primary | Differences of the group of patients with a persistent diagnosis of COVID from the age-matched group, sex and vaccination status of patients recovered from COVID without sequelae. | Through an algorithm model created by Machine Learning that will be trained using cardic variability (HRV), skin conductance and acoustic analysis data. | 8 weeks | |
Secondary | Cardiac variability | Number of times a contraction of the heart occurs in one minute, expressed in beats per minute, by means of a Polar chest strap, model H10. A baseline recording of 5 minutes duration will be taken, with the patient in a seated position. At the end of each test, recording is continued for 2 minutes to demonstrate the speed and degree of recovery after stress. | 8 weeks | |
Secondary | Voice recording | Sounds produced by the patient at rest and after having performed the stress tests. The patient will be asked to take a deep breath and then pronounce the vowel /a/ in a sustained manner, in a comfortable tone and volume (3 times). | 8 weeks | |
Secondary | Skin conductance | micro Siemens [µS]. By means of the Bitalino electrodermal activity recording system. It will be recorded at rest, during the Cold Pressor test and once it is finished, for at least two minutes, to assess the normalization of the conductivity curve. | 8 weeks | |
Secondary | 6MWT | metres/min. The patient will walk the maximum distance they can in 6 minutes. | 8 weeks | |
Secondary | 1minSTST | Number of repetitions performed after sitting down and getting up from a chair without supporting the hands as many times as possible for 1 minute.. | 8 weeks | |
Secondary | Cold Pressor test | One hand is inserted into a container with water at 4-5ºC for 1 minute. Before and after the test, HRV, BP, and thermal conductance are recorded for 5 and 2 minutes -respectively- while lying supine. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|